Skip to search formSkip to main contentSkip to account menu

CBL0137

Known as: FACT Complex-targeting Curaxin CBL0137 
An orally available curaxin-based agent targeting the Facilitates Chromatin Transcription (FACT) complex, with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyPositive Regulation of Apoptosis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
A Translational Hepatic Artery Infusion (HAI) Model for Hepatocellular Carcinoma in Woodchucks.
2020
2020
Novel anticancer drug curaxin CBL0137 impairs DNA methylation by eukaryotic DNA methyltransferase Dnmt3a.
2019
2019
Curaxin CBL0137 has the potential to reverse HIV‐1 latency
A cure for human immunodeficiency virus type‐1 (HIV‐1) has been hampered by the limitation of current combination antiretroviral… 
2019
2019
Prevention of Colorectal Carcinogenesis by DNA-Binding Small-Molecule Curaxin CBL0137 Involves Suppression of Wnt Signaling
Chemoprevention is considered a valid approach to reduce the incidence of colorectal cancer, one of the most common malignancies… 
2018
2018
The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells.
Traditional treatments of small-cell lung cancer (SCLC) with cisplatin, a standard-of-care therapy, spare the tumor-initiating… 
2018
2018
The FACT inhibitor CBL 0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH 1 Expression and Targeting Tumor-Initiating Cells
Traditional treatments of small-cell lung cancer (SCLC) with cisplatin, a standard-of-care therapy, spare the tumor-initiating… 
2017
2017
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program
CBL0137 is a novel drug that modulates FAcilitates Chromatin Transcription (FACT), resulting in simultaneous nuclear factor‐κB… 
2016
2016
Противоопухолевое действие кураксина cbl0137 на моделях аденокарциномы толстой кишки
Curaxins represent low molecular weight carbazole derivatives, which simultaneously activate p53-dependent apoptosis and inhibit… 
2016
2016
Abstract 3036: Targeting FACT complex with CBL0137 to overcome acquired resistance to EGFR-TKI in lung adenocarcinoma
Multiple randomized clinical trials have demonstrated that first line treatment with epidermal growth factor receptor tyrosine… 
2013
2013
Abstract 2759: Anticancer compound curaxin CBL0137, that simultaneously suppresses NF-κB and activates p53, is highly effective in two independent mouse models of neuroblastoma.
Background: We have reported that the anti-malarial drug, quinacrine (QC), has significant in vivo anti-tumor activity (Neznanov… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)